A FIRST-IN-HUMAN PHASE I STUDY TO EVALUATE THE DUAL PI3K/MTOR INHIBITOR GDC-0980 ADMINISTERED QD IN PATIENTS WITH ADVANCED SOLID TUMORS OR NON-HODGKIN S LYMPHOMA (NHL)

被引：0
|
作者：
Bendell, J. C. [1 ]
Wagner, A. J. [2 ]
Dolly, S.
Morgan, J. A. [2 ]
Papadatos-Pastos, D. [3 ]
Ware, J.
Mazina, K. E. [4 ]
Lauchle, J.
Burris, H. [1 ]
De Bono, J. [3 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Royal Marsden Hosp, Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[4] Genentech Inc, Res & Early Dev, San Francisco, CA 94080 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：162 / 163
页数：2
相关论文
共 50 条
  • [1] A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma
    Dolly, S.
    Wagner, A. J.
    Bendell, J. C.
    Yan, Y.
    Ware, J. A.
    Mazina, K. E.
    Holden, S. N.
    Derynck, M. K.
    De Bono, J. S.
    Burris, H. A., III
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
    Wagner, A. J.
    Bendell, J. C.
    Dolly, S.
    Morgan, J. A.
    Ware, J. A.
    Fredrickson, J.
    Mazina, K. E.
    Lauchle, J. O.
    Burris, H. A.
    De Bono, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Evaluation of tolerability and anti-tumor activity of GDC-0980, an oral PI3K/mTOR inhibitor, administered to patients with-advanced solid tumors or non-Hodgkin's lymphoma (NHL)
    Dolly, S.
    Bendell, J. C.
    Kindler, H. L.
    Lauchle, J. O.
    Krug, L. M.
    Seiwert, T. Y.
    Burris, H. A.
    DeBono, J. S.
    Wagner, A. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S162 - S162
  • [4] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITOR GDC-0980 IN PHASE I PATIENTS WITH ADVANCED SOLID TUMORS
    Jin, J. Y.
    Ware, J.
    Malhi, V.
    Upadhyay, S.
    Wu, J.
    Yan, Y.
    Lauchle, J.
    Holden, S.
    Derynck, M.
    Dresser, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S81 - S81
  • [5] A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors
    Von Hoff, D. D.
    LoRusso, P.
    Tibes, R.
    Shapiro, G.
    Weiss, G. J.
    Ware, J. A.
    Fredrickson, J.
    Mazina, K. E.
    Levy, G. G.
    Wagner, A. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors
    Wagner, A. J.
    Von Hoff, D. H.
    LoRusso, P. M.
    Tibes, R.
    Mazina, K. E.
    Ware, J. A.
    Yan, Y.
    Derynck, M. K.
    Demetri, G. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] A FIRST-IN-HUMAN PHASE I STUDY TO EVALUATE THE PAN-PI3K INHIBITOR GDC-0941 ADMINISTERED QD OR BID IN PATIENTS WITH ADVANCED SOLID TUMORS
    Wagner, A. J.
    Tibes, R.
    Shapiro, G. I.
    Iyengar, T.
    Demetri, G. D.
    Weiss, G. J.
    Fridlyand, J.
    Mazina, K. E.
    Levy, G. G.
    Lorusso, P. M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 163 - 163
  • [8] A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW
    Wagner, A. J.
    Jayson, G. C.
    Gomez-Roca, C.
    Zee, Y. K.
    Morgan, J. A.
    Yan, Y.
    Ware, J.
    Mazina, K. E.
    Lauchle, J.
    Soria, J. C.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 123 - 124
  • [9] A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours
    Von Hoff, D. D.
    Wagner, A. J.
    LoRusso, P. M.
    Tibes, R.
    Jin, J.
    Ware, J. A.
    Yan, Y.
    Derynck, M. K.
    Dolezal, M. V.
    Demetri, G. D.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 122 - 122
  • [10] Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
    Makker, Vicky
    Recio, Fernando O.
    Ma, Ling
    Matutonis, Ursula
    Lauchle, Jennifer O'Hara
    Parmar, Hema
    Gilbert, Houston
    Wang, Yulei
    Koeppen, Hartmut
    Spoerke, Jill M.
    Lackner, Mark
    Aghajanian, Carol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345